Lv31
390 积分 2024-10-19 加入
Effectiveness and Safety of Apremilast in Immune Checkpoint Inhibitor‐Associated Psoriasis: A Retrospective Multicenter Study From the EADV Task Force “Dermatology for Cancer Patients”
9小时前
已完结
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
7天前
已完结
Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies
10天前
已完结
Biologic treatment of psoriasis in oncologic patients
10天前
已完结
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group
13天前
已完结
COVID-19 vaccination around immune checkpoint inhibitor start and survival in a nationwide cohort of patients with cancer
17天前
已完结
Reply to: Limited benchmarks constrain the conclusions of a general-purpose versus clinical AI comparison
17天前
已完结
Limited benchmarks constrain the conclusions of a general-purpose versus clinical AI comparison
17天前
已完结
Successful treatment of PD1-inhibitor induced psoriasiform dermatitis using IL-17 blockade without compromising immunotherapy efficacy
1个月前
已完结
TNF: A Tumor-Suppressing Factor or a Tumor-Promoting Factor?
1个月前
已完结
皖公网安备34019202002308
